(R)-4-(3-aminomethyl-1,2,4-oxadiazol-5-yl)-1,3,4,5,6,7,8,9,10,12-decahydro-16-[dimethyl(thexyl)silyloxy]-14-methoxy-13-methyl-6-thioxo-11,2,5-benzoxathiaazacyclotetradecin-12-one | 173153-57-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (R)-4-(3-aminomethyl-1,2,4-oxadiazol-5-yl)-1,3,4,5,6,7,8,9,10,12-decahydro-16-[dimethyl(thexyl)silyloxy]-14-methoxy-13-methyl-6-thioxo-11,2,5-benzoxathiaazacyclotetradecin-12-one
• 英文别名: (R)-4-(3-Aminomethyl-1,2,4-oxadiazol-5-yl)-16-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxy]-14-methoxy-13-methyl-6-thioxo-1,3,4,5,6,7,8,9,10,12-decahydro-11,2,5-benzoxathiaazacyclotetradecin-12-one；(5R)-5-[3-(aminomethyl)-1,2,4-oxadiazol-5-yl]-18-[2,3-dimethylbutan-2-yl(dimethyl)silyl]oxy-16-methoxy-15-methyl-7-sulfanylidene-12-oxa-3-thia-6-azabicyclo[12.4.0]octadeca-1(18),14,16-trien-13-one
• CAS: 173153-57-6
• 化学式: C₂₈H₄₄N₄O₅S₂Si
• 分子量: 608.899
• InChiKey: GUCOWLXLYKKWPO-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  40
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  179
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (R)-4-(3-aminomethyl-1,2,4-oxadiazol-5-yl)-1,3,4,5,6,7,8,9,10,12-decahydro-16-[dimethyl(thexyl)silyloxy]-14-methoxy-13-methyl-6-thioxo-11,2,5-benzoxathiaazacyclotetradecin-12-one 在 溶剂黄146 、 sodium nitrite 作用下， 反应 1.0h， 生成
  参考文献：
  名称：

  New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine

  摘要：

  Cyclothialidine (1, Ro 09-1437) is a potent DNA gyrase inhibitor that was isolated from Streptomyces filipinensis NR0484 and is a member of a new family of natural products. It acts by competitively inhibiting the ATPase activity exerted by the B subunit of DNA gyrase but barely exhibits any growth inhibitory activity against intact bacterial cells, presumably due to insufficient permeation of the cytoplasmic membrane. To explore the antibacterial potential of 1, we developed a flexible synthetic route allowing for the systematic modification of its structure. From a first set of analogues, structure-activity relationships (SAR) were established for different substitution patterns, and the 14-hydroxylated, bicyclic core (X) of 1 seemed to be the structural prerequisite for DNA gyrase inhibitory activity. The variation of the lactone ring size, however, revealed that activity can be found among 11- to 16-membered lactones, and even seco-analogues were shown to maintain some enzyme inhibitory properties, thereby reducing the minimal structural requirements to a rather simple, hydroxylated benzyl sulfide (XI). On the basis of these "minimal structures" a modification program afforded a number of inhibitors that showed in vitro activity against Gram-positive bacteria. The best activities were displayed by 14-membered lactones, and representatives of this subclass exhibit excellent and broad in vitro antibacterial activity against Gram-positive pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, and overcome resistance against clinically used drugs. By improving the pharmacokinetic properties of the most active compounds (94, 97), in particular by lowering their lipophilic properties, we were able to identify congeners of cyclothialidine (1) that showed efficacy in vivo.

  DOI：

  10.1021/jm0310232
• 作为产物：
  描述：

  methyl 3,5-dimethoxy-2-methylbenzoate 在 劳森试剂 、 N-甲基吗啉 、 N-(三甲基硅基)吗啉 、 甲醇 、 三乙基硅烷 、 氢氧化钾 、 四(三苯基膦)钯 、 N,N-二甲基三甲基硅胺 、 三甲基硅乙酸酯 、 三氟乙酸三甲基硅酯 、 三氯化硼 、 对甲苯磺酸 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三乙胺 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 、 三氯氧磷 、 四甲基胍 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 130.5h， 生成 (R)-4-(3-aminomethyl-1,2,4-oxadiazol-5-yl)-1,3,4,5,6,7,8,9,10,12-decahydro-16-[dimethyl(thexyl)silyloxy]-14-methoxy-13-methyl-6-thioxo-11,2,5-benzoxathiaazacyclotetradecin-12-one
  参考文献：
  名称：

  New Antibacterial Agents Derived from the DNA Gyrase Inhibitor Cyclothialidine

  摘要：

  Cyclothialidine (1, Ro 09-1437) is a potent DNA gyrase inhibitor that was isolated from Streptomyces filipinensis NR0484 and is a member of a new family of natural products. It acts by competitively inhibiting the ATPase activity exerted by the B subunit of DNA gyrase but barely exhibits any growth inhibitory activity against intact bacterial cells, presumably due to insufficient permeation of the cytoplasmic membrane. To explore the antibacterial potential of 1, we developed a flexible synthetic route allowing for the systematic modification of its structure. From a first set of analogues, structure-activity relationships (SAR) were established for different substitution patterns, and the 14-hydroxylated, bicyclic core (X) of 1 seemed to be the structural prerequisite for DNA gyrase inhibitory activity. The variation of the lactone ring size, however, revealed that activity can be found among 11- to 16-membered lactones, and even seco-analogues were shown to maintain some enzyme inhibitory properties, thereby reducing the minimal structural requirements to a rather simple, hydroxylated benzyl sulfide (XI). On the basis of these "minimal structures" a modification program afforded a number of inhibitors that showed in vitro activity against Gram-positive bacteria. The best activities were displayed by 14-membered lactones, and representatives of this subclass exhibit excellent and broad in vitro antibacterial activity against Gram-positive pathogens, including Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, and overcome resistance against clinically used drugs. By improving the pharmacokinetic properties of the most active compounds (94, 97), in particular by lowering their lipophilic properties, we were able to identify congeners of cyclothialidine (1) that showed efficacy in vivo.

  DOI：

  10.1021/jm0310232

文献信息

• Mono- and bicyclic DNA gyrase inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US05589473A1

  公开（公告）日：1996-12-31

  The present invention relates to a compound of the formula ##STR1## wherein X.sup.1, R.sup.1, R.sup.2, OP, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.0 are as described herein, and their pharmaceutically acceptable salts thereof carrying an acidic and/or basic substituent. The compound of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.

  本发明涉及一种具有以下结构的化合物##STR1##其中X.sup.1、R.sup.1、R.sup.2、OP、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.0如本文所述，并且它们的药学上可接受的盐携带有酸性和/或碱性取代基。公式I的化合物以及它们的药学上可接受的盐抑制细菌中DNA旋转酶活性，并具有抗生素特别是抗菌活性，可用于控制或预防传染病。
• Tricyclic DNA gyrase inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US05594135A1

  公开（公告）日：1997-01-14

  The present invention relates to a compound of the formula ##STR1## wherein X.sup.1, R.sup.1, R.sup.2, OP, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.0 are as described herein, and their pharmaceutically acceptable salts thereof carrying an acidic and/or basic substituent. The compound of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.

  本发明涉及一种化合物，其化学式为##STR1##其中X.sup.1，R.sup.1，R.sup.2，OP，R.sup.3，R.sup.4，R.sup.5，R.sup.6和R.sup.0如本说明所述，并且它们的药学上可接受的酸性和/或碱性取代物质的盐。式I化合物及其药学上可接受的盐抑制细菌中的DNA酶活性，并具有抗生素，特别是抗微生物活性，可用于控制或预防传染病。